{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:22:52Z","timestamp":1793506972497,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.annonc.2019.10.015","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T02:40:36Z","timestamp":1578278436000},"page":"302-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types"],"prefix":"10.1016","volume":"31","author":[{"given":"X.","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ivaturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Statkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gobburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2019.10.015_bib1","series-title":"OPDIVO (nivolumab). Package Insert","year":"2019"},{"key":"10.1016\/j.annonc.2019.10.015_bib2","series-title":"OPDIVO (nivolumab). Summary of Product Characteristics","year":"2019"},{"key":"10.1016\/j.annonc.2019.10.015_bib3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.015_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","article-title":"Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy","volume":"4","author":"Agrawal","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2019.10.015_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.015_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.015_bib7","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.015_bib8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.015_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.015_bib10","author":"Food and Drug Administration"},{"key":"10.1016\/j.annonc.2019.10.015_bib11","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit\u2013risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.015_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.annonc.2019.10.015_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/psp4.12133","article-title":"Quantitative characterization of the exposure\u2013response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma","volume":"6","author":"Wang","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.annonc.2019.10.015_bib14","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1158\/1078-0432.CCR-16-2842","article-title":"Nivolumab exposure\u2013response analyses of efficacy and safety in previously treated squamous or nonsquamous non\u2013small cell lung cancer","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2019.10.015_bib15","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/jcph.962","article-title":"Exposure\u2013response analysis of nivolumab in patients with previously treated or untreated advanced melanoma","volume":"57","author":"Bajaj","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.annonc.2019.10.015_bib16","series-title":"OPDIVO (nivolumab). Product Monograph","year":"2019"},{"key":"10.1016\/j.annonc.2019.10.015_bib17","series-title":"OPDIVO (nivolumab). Product Information","year":"2018"},{"key":"10.1016\/j.annonc.2019.10.015_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.8_suppl.100","article-title":"CheckMate 384: phase IIIb\/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after \u2264 12 months of nivo in previously treated advanced NSCLC","volume":"37","author":"Garon","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.015_bib19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.015_bib20","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/annonc\/mdy408","article-title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","volume":"29","author":"Long","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419360703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419360703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:56:39Z","timestamp":1760334999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419360703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0923753419360703"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2019.10.015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2019.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}